- Motley Fool•3 hours ago
Nearly half of J&J's sales are now derived from its pharmaceutical segment, which has both good and bad implications.
- Motley Fool•5 hours ago
The biotech's stock took a hit due to disappointing midstage results for its experimental hepatitis C drug.
- Zacks•7 hours ago
Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let's see how things are shaping up for this quarter.
JNJ : Summary for Johnson & Johnson Common Stock - Yahoo Finance
Johnson & Johnson (JNJ)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
|Day's Range||123.04 - 123.75|
|52 Week Range||109.32 - 129.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||20.76|
|Dividend & Yield||3.20 (2.63%)|
|1y Target Est||N/A|